NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME Study)

Phase 1

Recruiting

Conditions: Normal Physiology
Healthy

Interventions: Other: Control
Drug: Amoxicillin
Drug: Azithromycin

First Posted Date: 2016-03-14

Last Posted Date: 2024-12-12

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 210

Registration Number: NCT02707042

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Screening for Alpha Thalassemia in Healthy Volunteers

Active, not recruiting

Conditions: Alpha Thalassemia

First Posted Date: 2016-02-26

Last Posted Date: 2024-11-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 367

Registration Number: NCT02692872

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

11C-5-HTP PET in Clinical Islet Transplantation

Not Applicable

Completed

Conditions: Type 1 Diabetes

First Posted Date: 2016-02-24

Last Posted Date: 2016-02-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 8

Registration Number: NCT02689479

Locations: 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
🇸🇪
Uppsala University, Uppsala, Sweden

Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine

Phase 1

Completed

Conditions: Dengue

Interventions: Biological: Placebo
Biological: rDEN3∆30

First Posted Date: 2016-02-18

Last Posted Date: 2016-11-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 14

Registration Number: NCT02684383

Locations: 🇺🇸
Center for Immunization Research (CIR), Johns Hopkins School of Public Health, Baltimore, Maryland, United States
🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States

Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh

Phase 2

Completed

Conditions: Dengue

Interventions: Biological: TV005 vaccine
Biological: Placebo

First Posted Date: 2016-02-09

Last Posted Date: 2020-08-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 192

Registration Number: NCT02678455

Locations: 🇧🇩
International Centre for Diarrhoeal Disease Research, Bangladesh, Mirpur, Dhaka, Bangladesh

Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection

Phase 2

Completed

Conditions: HIV Infections

Interventions: Biological: VRC01
Biological: Placebo for VRC01

First Posted Date: 2016-01-27

Last Posted Date: 2021-11-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 23

Registration Number: NCT02664415

Locations: 🇹🇭
SEARCH Thai Red Cross AIDS Research Centre Non-Network CRS, Bangkok, Thailand

Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)

Phase 4

Terminated

Conditions: Coccidioidomycosis

Interventions: Other: Placebo
Drug: Fluconazole

First Posted Date: 2016-01-26

Last Posted Date: 2019-07-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 72

Registration Number: NCT02663674

Locations: 🇺🇸
UCSF Fresno Center for Medical Education and Research - Clinical Research Center, Fresno, California, United States
🇺🇸
Banner - University Medical Center Advanced Lung Disease Clinic - Phoenix, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic, Phoenix - Infectious Diseases, Phoenix, Arizona, United States

and more 6 locations

Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso

Phase 1

Completed

Conditions: Plasmodium Falciparum Infection

Interventions: Drug: Artesunate
Biological: PfSPZ Vaccine
Other: Placebo

First Posted Date: 2016-01-26

Last Posted Date: 2019-07-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 112

Registration Number: NCT02663700

Locations: 🇧🇫
Centre National de Recherche et de Formation sur le Paludisme - Research and Training, Ouagadougou, Kadiogo, Burkina Faso

Impact of Antimalarial Treatment on Measures of T Cell Suppression/Regulation in Healthy Adults From Doneguebougou, Mali

Completed

Conditions: Malaria

First Posted Date: 2016-01-20

Last Posted Date: 2018-06-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 290

Registration Number: NCT02659566

Locations: 🇲🇱
Ouelessebougou Clinical Research Center, Bamako, Mali

Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: HIV-1 nef/tat/vif, env pDNA vaccine
Biological: Placebo
Biological: rVSV HIV envC vaccine

First Posted Date: 2016-01-13

Last Posted Date: 2021-10-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 14

Registration Number: NCT02654080

Locations: 🇺🇸
Case Clinical Research Site, Cleveland, Ohio, United States
🇺🇸
Penn Prevention CRS, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy